TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02054611

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online Educational Module
Description: A descriptive video detailing the diagnosis of ARDS according to the Berlin Definition, along with online educational materials available for review.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Evaluation First (Placebo)
Description: The respondents will view the descriptive video detailing the diagnosis of ARDS according to the Berlin Definition, along with online educational materials available for review only after they have completed the evaluation.
Study: NCT02854969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Device: Anapphylaxis
Study: NCT02802254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-targeted individual physical-activity-feedback
Description: At cardiac consultation receive an individual feedback on their personal physical activity level.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: Patients receive a pedometer two weeks prior to cardiac consultation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer
Description: Patients receive a pedometer two weeks prior to cardiac consultation.
Study: NCT01656733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotrol Inhaler
Description: Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
Study: NCT02366351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: Once daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: Once daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: Once daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily, 12 weeks
Study: NCT01732744

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiological solution
Description: The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hypochlorite
Description: The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alkaline Peroxide
Description: The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Castor bean solution
Description: The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
Study: NCT04977440

Intervention type: DIETARY_SUPPLEMENT
Intervention: Whey protein
Description: Patients were randomly divided into two groups: Group (A): Enteral feeding with normal protein intake ( 1.0 gm pin /kg/day ) Group (B): Enteral feeding with high protein intake ( 1.5- gm open /kg/day ) -Patient's- nonprotein- caloric intake was calculated according to REE :(25xactual body weight in kg ) and received it as follow : 1/2 the calculated amount of caloric intake in DAY 1 3/4 of the calculated amount of caloric intake in DAY 2~-Full calculated caloric amount in DAY 3~This regimen was followed long as the patient was tolerating the amount of feeding, and in case of intolerance:~The volume of feeding boluses was decreased or Increase the time interval between boluses or IV metoclopramide or erythromycin was given
Study: NCT04164134

Intervention type: OTHER
Intervention: blood draw
Description: Control samples for the Rb survivor group (adult) are already available at the VUMC for the platelet study; unselected volunteers from an anti-cancer campaign. Control samples (adult) for the EV study will be collected in a blooddrive at the Essen site.~Pediatric patients. For the pediatric Rb patients, blood draw is part of standard care (3mth-4y). The control blood samples of healthy children (12) will be drawn from healthy children, where the blood draw is already part of otherwise planned care (e.g. patients which are completely healthy besides having an unrelated problem for which surgery is required). Controls will be age-matched as much as possible.

Intervention type: OTHER
Intervention: blood draw
Description: Control samples for the Rb survivor group (adult) are already available at the VUMC for the platelet study; unselected volunteers from an anti-cancer campaign. Control samples (adult) for the EV study will be collected in a blooddrive at the Essen site.~Pediatric patients. For the pediatric Rb patients, blood draw is part of standard care (3mth-4y). The control blood samples of healthy children (12) will be drawn from healthy children, where the blood draw is already part of otherwise planned care (e.g. patients which are completely healthy besides having an unrelated problem for which surgery is required). Controls will be age-matched as much as possible.

Intervention type: OTHER
Intervention: blood draw
Description: Control samples for the Rb survivor group (adult) are already available at the VUMC for the platelet study; unselected volunteers from an anti-cancer campaign. Control samples (adult) for the EV study will be collected in a blooddrive at the Essen site.~Pediatric patients. For the pediatric Rb patients, blood draw is part of standard care (3mth-4y). The control blood samples of healthy children (12) will be drawn from healthy children, where the blood draw is already part of otherwise planned care (e.g. patients which are completely healthy besides having an unrelated problem for which surgery is required). Controls will be age-matched as much as possible.
Study: NCT01656733

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Inhaler
Description: Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
Study: NCT03012698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ocular Repetitive Magnetic Stimulation (RMS) treatment
Description: First stage: Patients will be asked to undergo a one-time treatment with Epitech Corneal Magnetic Stimulation Device on one eye. The worst eye will be treated; if both eyes are equal, the right eye will be treated.~Second stage: will be treated on both eyes, applying treatment to both eyes sequentially during the same visit.
Study: NCT01875549

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stent insertion
Description: to use a LCD stent at an unilateral or bilateral stent insertion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stent insertion
Description: to use a LCD stent at an unilateral or bilateral stent insertion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatoscopy(ERCP)
Description: to use ERCP for a stent insertion in an obstructive biliary tract

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatoscopy(ERCP)
Description: to use ERCP for a stent insertion in an obstructive biliary tract
Study: NCT04580342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral Ivabradine
Description: Ivabradine group will receive ivabradine 5mg PO in the evening and 1 hour before anesthetic induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral Propranolol
Description: propranolol group will receive propranolol 10 mg PO in the evening and 1 hour before anesthetic induction.
Study: NCT01102010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Description: An expanded indication for blood transfusion in the frail elderly
Study: NCT00539565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Description: 2 mg/kg /day from post-op day 7 - day 21~1 mg/kg /day from post-op day 22 - day 30
Study: NCT04164134

Intervention type: OTHER
Intervention: blood draw
Description: Control samples for the Rb survivor group (adult) are already available at the VUMC for the platelet study; unselected volunteers from an anti-cancer campaign. Control samples (adult) for the EV study will be collected in a blooddrive at the Essen site.~Pediatric patients. For the pediatric Rb patients, blood draw is part of standard care (3mth-4y). The control blood samples of healthy children (12) will be drawn from healthy children, where the blood draw is already part of otherwise planned care (e.g. patients which are completely healthy besides having an unrelated problem for which surgery is required). Controls will be age-matched as much as possible.

Intervention type: OTHER
Intervention: blood draw
Description: Control samples for the Rb survivor group (adult) are already available at the VUMC for the platelet study; unselected volunteers from an anti-cancer campaign. Control samples (adult) for the EV study will be collected in a blooddrive at the Essen site.~Pediatric patients. For the pediatric Rb patients, blood draw is part of standard care (3mth-4y). The control blood samples of healthy children (12) will be drawn from healthy children, where the blood draw is already part of otherwise planned care (e.g. patients which are completely healthy besides having an unrelated problem for which surgery is required). Controls will be age-matched as much as possible.
Study: NCT01057849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: 3-6 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: 3-6 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 5-20 mg per day
Study: NCT00539565

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03469531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Patients receive nimotuzumab IV over 90 minutes on days 1, 8, 15, 22, 29, 36,43.
Study: NCT01057849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: 5-20 mg per day
Study: NCT03469531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Patients undergo cisplatin, 25-40 mg/m2 a week for 4 or 5weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients undergo cisplatin, 25-40 mg/m2 a week for 4 or 5weeks
Study: NCT01057849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: 10-30 mg per day
Study: NCT03469531

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: external-beam radiation
Description: Patients undergo pelvic EBRT once daily, 5 days a week, for 5 weeks for a total of 45-50.4Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external-beam radiation
Description: Patients undergo pelvic EBRT once daily, 5 days a week, for 5 weeks for a total of 45-50.4Gy
Study: NCT01057849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: 10-30 mg per day
Study: NCT03022877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: In a prospective randomized setting, patients are included with an acute STEMI of the anterior wall. A bolus administration Levosimendan with/without following continuous infusion over 24 hours compared to a control group (placebo) will be examined. The initiation of therapy is carried out for 10 min. prior to reperfusion. The coronary Intervention is performed immediately after inclusion at the latest within 6 hours after the onset of symptoms. The administration of Levosimendan is based on a fixed schema: Bolus: 12 µg/kg over 10 min I. V., starting 10 min before recanalization and an addition of 0.1-0.2 µg/kg/min i. v. for 24 hours in the continuous infusion group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: In a prospective randomized setting, patients are included with an acute STEMI of the anterior wall. A bolus administration Levosimendan with/without following continuous infusion over 24 hours compared to a control group (placebo) will be examined. The initiation of therapy is carried out for 10 min. prior to reperfusion. The coronary Intervention is performed immediately after inclusion at the latest within 6 hours after the onset of symptoms. The administration of Levosimendan is based on a fixed schema: Bolus: 12 µg/kg over 10 min I. V., starting 10 min before recanalization and an addition of 0.1-0.2 µg/kg/min i. v. for 24 hours in the continuous infusion group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levosimendan
Description: In a prospective randomized setting, patients are included with an acute STEMI of the anterior wall. A bolus administration Levosimendan with/without following continuous infusion over 24 hours compared to a control group (placebo) will be examined. The initiation of therapy is carried out for 10 min. prior to reperfusion. The coronary Intervention is performed immediately after inclusion at the latest within 6 hours after the onset of symptoms. The administration of Levosimendan is based on a fixed schema: Bolus: 12 µg/kg over 10 min I. V., starting 10 min before recanalization and an addition of 0.1-0.2 µg/kg/min i. v. for 24 hours in the continuous infusion group.
Study: NCT03116516

Intervention type: DRUG
Group type: OTHER
Intervention: Temisartan/Amlodipine+Rosuvastatin
Description: All subjects will receive a single oral dose of temisartan/amlodipine+rosuvastatin administered in the morning.

Intervention type: DRUG
Group type: OTHER
Intervention: Temisartan/Amlodipine+Rosuvastatin
Description: All subjects will receive a single oral dose of temisartan/amlodipine+rosuvastatin administered in the morning.
Study: NCT03469531

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: brachytherapy
Description: high-dose rate brachytherapy,6Gy once weekly,for a total of 24-30Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: high-dose rate brachytherapy,6Gy once weekly,for a total of 24-30Gy
Study: NCT02731183

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation
Description: Patients received frozen FMT on 6 consecutive days through nasojejunal tubes.
Study: NCT02084173

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MET + CRA

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MET + CRA
Study: NCT00801931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Each dose of alemtuzumab is to be diluted in 5% dextrose in water (D5W) or normal saling (NS) (maximum concentration: 0.3 mg/mL) for intravenous (IV) infusion over two hours.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 45mg/m2 (1.5 mg/kg IV for children \<1 year of age or \<10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: (Busulfex) will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration \>0.5 mg/mL), through a central venous access device over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: (Busulfex) will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration \>0.5 mg/mL), through a central venous access device over 2 hours.
Study: NCT03116516

Intervention type: DRUG
Group type: OTHER
Intervention: YHP1604
Description: All subjects will receive a single oral dose of YHP1604 administered in the morning.

Intervention type: DRUG
Group type: OTHER
Intervention: YHP1604
Description: All subjects will receive a single oral dose of YHP1604 administered in the morning.
Study: NCT03705052

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Patients and caregivers were asked to complete a questionnaire
Study: NCT04706949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib combined with pemetrexed plus carboplatin
Description: 1. Pyrotinib: oral administration within 30 minutes after breakfast, 400mg / day, continuous administration for 21 days as a cycle; each continuous pause time and the cumulative pause time of each cycle should not exceed 14 days. It is allowed to suspend the drug for many times due to adverse events.~2. Pemetrexed: the recommended dosage is 500mg / m2, once every three weeks. 3) Carboplatin: the dosage was determined according to Calvert formula, in which AUC was 5mg / ml / min.
Study: NCT01137032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pandel Cream 0.1%
Description: A thin coat of cream will be applied and rubbed into the affected areas, as well as normal skin, twice daily for 21 days
Study: NCT02800616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Healthy Primary School of the Future
Description: In two out of four intervention schools, a whole-school approach named 'The Healthy Primary School of the Future', is implemented with the aim of improving physical activity and dietary behaviour. For this intervention, pupils are offered an extended curriculum, including a healthy lunch, more physical exercises, and social and educational activities, next to the regular school curriculum.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Physical Activity School
Description: In the two other intervention schools, a physical-activity school approach called 'The Physical Activity School', is implemented, which is essentially similar to the other intervention, except that no lunch is provided.
Study: NCT04585282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plus Cognitive behavioral therapy of insomnia（CBT-I plus）
Description: Cbt-i plus program is an enhanced version of cbt-i program, which increases the response to depression and anxiety symptoms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy of insomnia（CBT-I）
Description: Cognitive behavioral therapy of insomnia is mainly aimed at correcting the bad behaviors and beliefs among the maintenance factors of insomnia, which is considered as the first-line treatment program of insomnia disorder. Cognitive behavioral therapy of insomnia mainly includes five important components: sleep restriction, secondary control, cognitive therapy, relaxation therapy and sleep hygiene.
Study: NCT01576432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assess pain with the NIPS score
Description: In group 1 (BF+SSC), neonates dressed with a diaper were held in prone, in SSC with the mother; BF was started at least 5 minutes before heel lance and maintained during sampling. In group 2 (sucrose + SSC), neonates were held in prone between the mothers' breast at least 5 minutes before sampling and 2 ml 24% sucrose was given with a sterile syringe in the mouth 2 minutes before heel lance. In group 3 (SSC), neonates were held between the mother's breast as in group 2, but no sucrose was given. In group 4 (Sucrose), 2 ml 24% sucrose was administered through a sterile syringe in the mouth 2 minutes before heel lance to neonates laid on supine on a cot; the procedure was done in the presence of the mother. Mothers were allowed to speak or touch their babies in all the groups.
Study: NCT00801931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: (Busulfex) will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration \>0.5 mg/mL), through a central venous access device over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: (Busulfex) will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration \>0.5 mg/mL), through a central venous access device over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: Fosphenytoin can be administered in D5W or 0.9% sodium chloride to a final concentration ranging from 1.5 to 25 mg PE/ml at a rate of 1-3 mg phenytoin sodium equivalents (PE)/kg/min up to 50-150 mg PE/minute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.